| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-05-16 | autologous genetically modified T-cells expressing an affinity optimized T-cell receptor (TCR) specific for MAGE-A4 | solid tumors (inoperable locally advanced or metastatic melanoma, and urothelial, head and neck, ovarian, non-small cell lung, esophageal, and gastric cancers expressing MAGE-A4) | 1 | Adaptimmune (UK) | Cancer - Oncology |
| 2017-05-15 | IVA337 - lanifibranor - 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid) | preclinical | Inventiva Pharma (France) | ||
| 2017-05-15 | Strensiq® (asfotase alfa) | hypophosphatasia | Alexion Pharmaceuticals (USA - CT) | Rare diseases - Genetic diseases - Metabolic diseases | |
| 2017-05-12 | obeticholic acid (OCA) | NASH (non-alcoholic steatohepatitis) | 2b | Intercept Pharmaceuticals (USA - NY) | Liver diseases - Hepatic diseases |
| 2017-05-12 | tafenoquine | malaria | 3 | GSK (UK) Medicines for Malaria Venture (MMV) | Infectious diseases - Parasitic diseases |
| 2017-05-12 | PL265 | ocular pain | preclinical | Pharmaleads (France) | Ophtalmological diseases |
| 2017-05-12 | VB-111 (ofranergene obadenovec) and immune checkpoint inhibitor | lung cancer, melanoma | preclinical | VBL Therapeutics (Israel) | Cancer - Oncology |
| 2017-05-11 | AR101 | peanut allergy | 3 | Aimmune Therapeutics (USA - CA) previously Allergen Research Corporation (ARC) | Allergic diseases |
| 2017-05-11 | Sarconeos (formerly SARCOB BIO101) | sarcopenia | 2 | Biophytis (France) | Muscle disorders |
| 2017-05-10 | tralokinumab | severe, inadequately controlled asthma |
3 | AstraZeneca (UK) | Allergic diseases - Immunological diseases - Respiratory diseases |
| 2017-05-10 | ophthalmic solithromycin | preclinical | Cempra (USA - NC) | Infectious diseases | |
| 2017-05-10 | mepolizumab | chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype | 3 | GSK (UK) | Inflammatory diseases - Respiratory diseases |
| 2017-05-10 | Tecentriq® (atezolizumab) (MPDL3280A) | metastatic urothelial carcinoma | 3 | Roche (Switzerland) | Cancer - Oncology |
| 2017-05-10 | autologous genetically modified T-cells expressing affinity enhanced T-cell receptors (TCRs) specific for alpha fetoprotein (AFP) | locally advanced or metastatic hepatocellular carcinoma | 1 | Adaptimmune Therapeutics (UK) | Cancer - Oncology |
| 2017-05-09 | EYS606 | non-infectious uveitis (NIU) | 1-2 | Eyevensys (France) | Rare diseases - Ophtalmological diseases |
| 2017-05-09 | binimetinib and encorafenib | BRAF-mutant advanced, unresectable or metastatic melanoma | 3 | Array BioPharma (USA - CO) Pierre Fabre (France) | Cancer - Oncology |
| 2017-05-09 | abicipar pegol (anti-VEGF DARPin - AGN-150998/MP0112) | wet age-related macular degeneration (wet AMD) | 3 | Molecular Partners (Switzerland) Allergan (Ireland) | Ophtalmological diseases |
| 2017-05-09 | pegunigalsidase alfa (PRX-102 - alpha-galactosidase-A) | Fabry disease | 3 | Protalix BioTherapeutics (Israel) | Rare diseases - Genetic diseases |
| 2017-05-09 | Keyzilen™ (AM-101) | acute peripheral tinnitus | 3 | Auris Medical (Switzerland) | Otorhinolaryngology |
| 2017-05-09 | Trulance™ (plecanatide) | irritable bowel syndrome with constipation (IBS-C) | 3 | Synergy Pharmaceuticals (USA - NY) | Digestive diseases - Gastrointestinal diseases - Inflammatory diseases |
